Suchergebnisse - "Tibaldi, Carmelo"

PubPharm (65)

1

Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression

enthalten in: Translational oncology | 2024

von Del Re, M. | Luculli, G. | Petrini, I. | +21

2

Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer : Analysis of Prognostic Factors of Outcomes

enthalten in: Anti-cancer agents in medicinal chemistry | 2022

von Tibaldi, C. | Mazzoni, F. | Scotti, V. | +15

3

Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes

enthalten in: Anti-cancer agents in medicinal chemistry | 2022

von Tibaldi, C. | Mazzoni, F. | Scotti, V. | +15

4

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib : Implications for Clinical Resistance

enthalten in: Cancers | 2020

von Honeywell, R. | Kathmann, I. | Giovannetti, E. | +5

5

A reply to "Immune related adverse events and response to immunotherapy : focus on corticosteroids."

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2020

von Baldini, E. | Tibaldi, C.

CommentOn: Lung Cancer. 2020 Feb;140:59-64. - PMID 31881412

6

Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab : The Italian NSCLC expanded access program

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2020

von Baldini, E. | Lunghi, A. | Cortesi, E. | +19

CommentIn: Lung Cancer. 2020 Jul;145:225. - PMID 32089331

7

Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer : a prospective validation study

enthalten in: British journal of cancer | 2018

von Tibaldi, C. | Camerini, A. | Tiseo, M. | +12

8

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer

enthalten in: Oncotarget | 2018

von Toffalorio, F. | Santarpia, M. | Radice, D. | +13

9

Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors

enthalten in: World journal of clinical oncology | 2017

von Tibaldi, C. | Lunghi, A. | Baldini, E.

10

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer : The GOIRC-AIFA FARM6PMFJM Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Tiseo, M. | Boni, L. | Ambrosio, F. | +16

CommentIn: J Clin Oncol. 2017 Apr 20;35(12):1269-1271. - PMID 28165898

1
2
3
4
5
6
7
Nächster »
[7]